<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01937234</url>
  </required_header>
  <id_info>
    <org_study_id>AFHSR-13-7-2013</org_study_id>
    <nct_id>NCT01937234</nct_id>
  </id_info>
  <brief_title>Use of an Antiemetic to Shorten the Length of Labor in Nulliparous Women</brief_title>
  <official_title>Use of an Antiemetic to Shorten the Length of Labor in Nulliparous Women, Exploring a Potential Role of an Old Drug</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Armed Forces Hospitals, Southern Region, Saudi Arabia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Reducing the length of labor is a highly desirable goal of intrapartum care, both from a
      perspective of maternal and fetal well-being , and for the providers of the birth services.
      Avoiding a long , protracted labor entails shorter exposure to pain anxiety and stress and
      would translate into a major improvement in maternal satisfaction with the child birth
      experience.

      The purpose of this study is to determine the effectiveness of metoclopramide for reducing
      the duration of spontaneous labor among nulliparous women managed according to a standard
      intrapartum protocol.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Women who will fulfill the study inclusion and exclusion criteria and agree to be included in
      the study will be randomized assigned to receive either an intravenous injection of 10mg
      metoclopramide (Group 1) or the same volume of placebo, i.e. 0.9% sodium chloride (Group2).
      Randomization will be achieved using computer generated randomization sequences. Allocation
      will be in 1:1 ratio. Record of group allocation will be maintained by a resident physician
      whose responsibility is randomization and drawing up the injection, but has no direct
      involvement in the intrapartum decision making.

      After through history and physical examination, each participant will take the selected
      medication slowly IV over 2 min, the assigned medication will be repeated every two hours for
      a maximum of three doses.

      Monitoring of fetal well-being and labor progress with Partographic representation will be
      performed.

      Management of labor will be according the labor and delivery standard protocol, if labor
      dilatation will not progress appropriately, i.e. cervical dilatation rate of &lt;1cm/hour,
      amniotomy will be performed if membranes are intact. Oxytocin augmentation will be considered
      after rupture of membranes only if the cervix remains unchanged on two consecutive pelvic
      examination conducted two hours apart. Oxytocin infusion will start with 5mIU/min and
      increase by 5mIU/min every 15min to achieve seven contractions in 15 min, the maximal rate of
      oxytocin being 30Miu/min.

      The following parameters will be recorded for every patient:

        -  Timing of metoclopramide or placebo injections

        -  Timing of full dilatation of cervix

        -  Duration of first stage of labor

        -  Duration of second stage of labor

        -  Duration of third stage of labor

        -  Mode of delivery

        -  Injection to delivery interval

        -  Cervical dilatation rate

        -  Neonatal condition at birth
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cervical dilatation rate</measure>
    <time_frame>6 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of the first stage of labor</measure>
    <time_frame>6 hours</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Duration of the second stage of labor</measure>
    <time_frame>2 hours</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Duration of the third stage of labor</measure>
    <time_frame>1 hour</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number of Participants with Adverse Events</measure>
    <time_frame>24 hours</time_frame>
    <description>Adverse effects of metoclopramide:
Cardiovascular: heart block, bradycardia, heart failure, flushing, hyper or hypotension, supraventricular tachycardia.
Central nervous system: Drowsiness, acute dystonic reactions, headache, dizziness, akathisia, confusion, depression, hallucinations, Parkinsonian-like symptoms, suicidal ideation, seizure, tardive dyskinesia
Dermatologic: Angioneurotic edema, rash, urticaria
Gastrointestinal: Nausea, vomiting, diarrhea
Respiratory: Bronchospasm, laryngeal edema (rare), laryngospasm (rare)</description>
  </other_outcome>
  <other_outcome>
    <measure>Apgar score</measure>
    <time_frame>10 minutes</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Meconium stained liquor</measure>
    <time_frame>6 hours</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Neonatal intensive care unit admission rate</measure>
    <time_frame>24 hours</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Rate of vaginal delivery</measure>
    <time_frame>12 hours</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number of participants with genital tract injuries</measure>
    <time_frame>2 hours</time_frame>
    <description>genital tract injuries:
Perineal tears
Vaginal tears
Cervical tears
Perineal hematomas
Vaginal hematomas
Uterine rupture</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">250</enrollment>
  <condition>Prolonged First Stage of Labor</condition>
  <arm_group>
    <arm_group_label>Metoclopramide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intravenous injection of 10mg metoclopramide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intravenous injection of 0.9% sodium chloride</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metoclopramide</intervention_name>
    <description>Intravenous injection of 10mg metoclopramide, at enrollment, then every 2 hours.
Maximum of 3 doses.</description>
    <arm_group_label>Metoclopramide</arm_group_label>
    <other_name>Primperan (Trademark)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Intravenous injection of 0.9% sodium chloride, at enrollment, then every 2 hours.
Maximum of 3 doses.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Normal saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Primigravida

          -  Singleton pregnancy

          -  Term gestation i.e. 37- 42 weeks

          -  Sure reliable dates

          -  Vertex presentation, occipitoanterior position

          -  Spontaneous onset of labor

          -  Regular uterine contractions at every 5 min ,each lasting for 20 sec

          -  Cervical dilatation of 3-5cm

          -  With or without rupture of membranes

          -  No evidence of maternal or fetal distress

        Exclusion Criteria:

          -  Mal-presentations

          -  Mal-positions

          -  Multifetal pregnancy

          -  Cephalopelvic disproportion

          -  history of cervical surgery or injury

          -  Hypersensitivity to metoclopramide
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohamed I Ellaithy, MD</last_name>
    <role>Study Director</role>
    <affiliation>Ain Shams University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Labor and delivery ward of Armed Forces Hospital, Southern Region.</name>
      <address>
        <city>Khamis Mushait</city>
        <zip>101</zip>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Saudi Arabia</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 1, 2013</study_first_submitted>
  <study_first_submitted_qc>September 4, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2013</study_first_posted>
  <last_update_submitted>March 9, 2017</last_update_submitted>
  <last_update_submitted_qc>March 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Mohamed Ellaithy</investigator_full_name>
    <investigator_title>Lecturer of Obstetrics &amp; Gynecology</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metoclopramide</mesh_term>
    <mesh_term>Antiemetics</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

